English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Despite extensive preclinical evidence that peroxisome proliferator-activated receptor (PPAR)  γ   activation protects against tumourigenesis, results from a few clinical trials using PPAR  γ   ligands as monotherapy show modest success. In spite of this, several groups reported exciting results with therapeutic regimens that combine PPAR  γ   ligands with other compounds: chemotherapeutic agents, retinoid x receptor (RXR)  α   agonists, statins, or cell-to-cell signaling molecules in preclinical cancer models and human trials. Here we have compiled an extensive review, consolidating the existing literature, which overwhelmingly supports a beneficial effect of treating with PPAR  γ   ligands in combination with existing chemotherapies versus their monotherapy in cancer. There are many examples in which combination therapy resulted in synergistic/additive effects on apoptosis, differentiation, and the ability to reduce cell growth and tumour burden. There are also studies that indicate that PPAR  γ   ligand pretreatment overcomes resistance and reduces toxicities. Several mechanisms are explored to explain these protective effects. This paper highlights each of these studies that, collectively, make a very strong case for the use of PPAR  γ   ligands in combination with other agents in the treatment and management of several cancers.

The Key to Unlocking the Chemotherapeutic Potential of PPARγLigands: Having the Right Combination